Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RePASS-II: toripalimab plus SBRT re-irradiation for recurrent or second primary head and neck squamous cell carcinoma
ChiCTR2100049819Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: objective response rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100049819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049819.